JP6407285B2 - RORγ調節因子 - Google Patents
RORγ調節因子 Download PDFInfo
- Publication number
- JP6407285B2 JP6407285B2 JP2016540455A JP2016540455A JP6407285B2 JP 6407285 B2 JP6407285 B2 JP 6407285B2 JP 2016540455 A JP2016540455 A JP 2016540455A JP 2016540455 A JP2016540455 A JP 2016540455A JP 6407285 B2 JP6407285 B2 JP 6407285B2
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- alkyl
- bicyclic
- monocyclic
- membered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CC1C=CC*1(C)C Chemical compound CC1C=CC*1(C)C 0.000 description 11
- FZMPLKVGINKUJZ-UHFFFAOYSA-N Cc(cc1)cc(F)c1F Chemical compound Cc(cc1)cc(F)c1F FZMPLKVGINKUJZ-UHFFFAOYSA-N 0.000 description 2
- VCZNNAKNUVJVGX-UHFFFAOYSA-N Cc(cc1)ccc1C#N Chemical compound Cc(cc1)ccc1C#N VCZNNAKNUVJVGX-UHFFFAOYSA-N 0.000 description 2
- NPDACUSDTOMAMK-UHFFFAOYSA-N Cc(cc1)ccc1Cl Chemical compound Cc(cc1)ccc1Cl NPDACUSDTOMAMK-UHFFFAOYSA-N 0.000 description 2
- WRWPPGUCZBJXKX-UHFFFAOYSA-N Cc(cc1)ccc1F Chemical compound Cc(cc1)ccc1F WRWPPGUCZBJXKX-UHFFFAOYSA-N 0.000 description 2
- CHLICZRVGGXEOD-UHFFFAOYSA-N Cc(cc1)ccc1OC Chemical compound Cc(cc1)ccc1OC CHLICZRVGGXEOD-UHFFFAOYSA-N 0.000 description 2
- VXLYOURCUVQYLN-UHFFFAOYSA-N Cc(cc1)cnc1Cl Chemical compound Cc(cc1)cnc1Cl VXLYOURCUVQYLN-UHFFFAOYSA-N 0.000 description 2
- WWYQUVRQRXJULJ-UHFFFAOYSA-N Cc1cc(OCCN2C)c2nc1 Chemical compound Cc1cc(OCCN2C)c2nc1 WWYQUVRQRXJULJ-UHFFFAOYSA-N 0.000 description 2
- YKIVWXBPOOHWHJ-UHFFFAOYSA-N O=C(Nc1c(C2)cccc1)N2S Chemical compound O=C(Nc1c(C2)cccc1)N2S YKIVWXBPOOHWHJ-UHFFFAOYSA-N 0.000 description 2
- UASPUKAUCYOONN-UHFFFAOYSA-N CC(C)(C)OC(N1c2ccccc2CCC1O)=O Chemical compound CC(C)(C)OC(N1c2ccccc2CCC1O)=O UASPUKAUCYOONN-UHFFFAOYSA-N 0.000 description 1
- XPXWAMCRUWVOFQ-UHFFFAOYSA-N CC(C)(CNC(Cc1cc(F)ccc1S(N1c2ccc(C(C(F)(F)F)(C(F)(F)F)O)cc2CCC1)(=O)=O)=O)N Chemical compound CC(C)(CNC(Cc1cc(F)ccc1S(N1c2ccc(C(C(F)(F)F)(C(F)(F)F)O)cc2CCC1)(=O)=O)=O)N XPXWAMCRUWVOFQ-UHFFFAOYSA-N 0.000 description 1
- BMPNKLCPHIYLRR-HXBUSHRASA-N CC(CC1)(CN1C(C[C@H](CCc1cc(C(C(F)(F)F)(C(F)(F)F)O)ccc11)N1S(c(cc1)ccc1F)(=O)=O)=O)O Chemical compound CC(CC1)(CN1C(C[C@H](CCc1cc(C(C(F)(F)F)(C(F)(F)F)O)ccc11)N1S(c(cc1)ccc1F)(=O)=O)=O)O BMPNKLCPHIYLRR-HXBUSHRASA-N 0.000 description 1
- VLCLQKKUIXVTTE-UHFFFAOYSA-N CC(CN(Cc1ccccc1)Cc1ccccc1)(C(N1CF)=O)NC1=O Chemical compound CC(CN(Cc1ccccc1)Cc1ccccc1)(C(N1CF)=O)NC1=O VLCLQKKUIXVTTE-UHFFFAOYSA-N 0.000 description 1
- DSCWHNKZIWFACR-UHFFFAOYSA-N CN(C1)CNC1=O Chemical compound CN(C1)CNC1=O DSCWHNKZIWFACR-UHFFFAOYSA-N 0.000 description 1
- BXPUSDJPGORRAZ-UHFFFAOYSA-N CN(CC1)CCC1(c1ccccc1N1)OC1=O Chemical compound CN(CC1)CCC1(c1ccccc1N1)OC1=O BXPUSDJPGORRAZ-UHFFFAOYSA-N 0.000 description 1
- YLBQJBFSUOBZMA-SFHVURJKSA-N NC([C@H](CC(C1)(F)F)N1C(Cc1cc(F)ccc1S(N1c2ccc(C(C(F)(F)F)(C(F)(F)F)O)cc2CCC1)(=O)=O)=O)=O Chemical compound NC([C@H](CC(C1)(F)F)N1C(Cc1cc(F)ccc1S(N1c2ccc(C(C(F)(F)F)(C(F)(F)F)O)cc2CCC1)(=O)=O)=O)=O YLBQJBFSUOBZMA-SFHVURJKSA-N 0.000 description 1
- WOOJYBRETVZTMI-ROUUACIJSA-N N[C@@H](CC1)CN1C(C[C@H](CCc1cc(C(C(F)(F)F)(C(F)(F)F)O)ccc11)N1S(c(cc1)ccc1F)(=O)=O)=O Chemical compound N[C@@H](CC1)CN1C(C[C@H](CCc1cc(C(C(F)(F)F)(C(F)(F)F)O)ccc11)N1S(c(cc1)ccc1F)(=O)=O)=O WOOJYBRETVZTMI-ROUUACIJSA-N 0.000 description 1
- SZSDNGOPLYKUQL-UHFFFAOYSA-N OC(C(F)(F)F)(C(F)(F)F)c(cc1)cc(CCC2C(O)=O)c1N2S(c(cc1)ccc1F)(=O)=O Chemical compound OC(C(F)(F)F)(C(F)(F)F)c(cc1)cc(CCC2C(O)=O)c1N2S(c(cc1)ccc1F)(=O)=O SZSDNGOPLYKUQL-UHFFFAOYSA-N 0.000 description 1
- SLNICQZZTIMVDU-NVHKAFQKSA-N OC(C(F)(F)F)(C(F)(F)F)c(cc1CC[C@H]2CC(N(CC3)CC3(C(N3)=O)NC3=O)=O)ccc1N2S(c(cc1)ccc1F)(=O)=O Chemical compound OC(C(F)(F)F)(C(F)(F)F)c(cc1CC[C@H]2CC(N(CC3)CC3(C(N3)=O)NC3=O)=O)ccc1N2S(c(cc1)ccc1F)(=O)=O SLNICQZZTIMVDU-NVHKAFQKSA-N 0.000 description 1
- NULKBXRLIDQIMK-CGAIIQECSA-N OC(C(F)(F)F)(C(F)(F)F)c(cc1CC[C@H]2CC(N(CC3)CC3NC(c3ccccc3)=O)=O)ccc1N2S(c(cc1)ccc1F)(=O)=O Chemical compound OC(C(F)(F)F)(C(F)(F)F)c(cc1CC[C@H]2CC(N(CC3)CC3NC(c3ccccc3)=O)=O)ccc1N2S(c(cc1)ccc1F)(=O)=O NULKBXRLIDQIMK-CGAIIQECSA-N 0.000 description 1
- LEZVJLHMDYPHQY-HNNXBMFYSA-N OC(C(F)(F)F)(C(F)(F)F)c(cc1CC[C@H]2CC(NCC(O)=O)=O)ccc1N2S(c(cc1)ccc1F)(=O)=O Chemical compound OC(C(F)(F)F)(C(F)(F)F)c(cc1CC[C@H]2CC(NCC(O)=O)=O)ccc1N2S(c(cc1)ccc1F)(=O)=O LEZVJLHMDYPHQY-HNNXBMFYSA-N 0.000 description 1
- HODWZBJHXZYQBH-KRWDZBQOSA-N OC(C1)CN1C(CNC(C[C@H](CCc1cc(C(C(F)(F)F)(C(F)(F)F)O)ccc11)N1S(c(cc1)ccc1F)(=O)=O)=O)=O Chemical compound OC(C1)CN1C(CNC(C[C@H](CCc1cc(C(C(F)(F)F)(C(F)(F)F)O)ccc11)N1S(c(cc1)ccc1F)(=O)=O)=O)=O HODWZBJHXZYQBH-KRWDZBQOSA-N 0.000 description 1
- BLBDURVDDQPEOM-INIZCTEOSA-N OC(C1)CN1C(C[C@H](CCc1c2ccc(C(C(F)(F)F)(C(F)(F)F)O)c1)N2S(c(cc1)ccc1F)(=O)=O)=O Chemical compound OC(C1)CN1C(C[C@H](CCc1c2ccc(C(C(F)(F)F)(C(F)(F)F)O)c1)N2S(c(cc1)ccc1F)(=O)=O)=O BLBDURVDDQPEOM-INIZCTEOSA-N 0.000 description 1
- GSTDINZZKFXQTI-ROUUACIJSA-N O[C@@H](CC1)CN1C(C[C@H](CCc1cc(C(C(F)(F)F)(C(F)(F)F)O)ccc11)N1S(c(cc1)ccc1F)(=O)=O)=O Chemical compound O[C@@H](CC1)CN1C(C[C@H](CCc1cc(C(C(F)(F)F)(C(F)(F)F)O)ccc11)N1S(c(cc1)ccc1F)(=O)=O)=O GSTDINZZKFXQTI-ROUUACIJSA-N 0.000 description 1
- XSDFTPCIEJPJPU-UHFFFAOYSA-N SN1CC2OC2C1 Chemical compound SN1CC2OC2C1 XSDFTPCIEJPJPU-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
- C07D279/16—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361875220P | 2013-09-09 | 2013-09-09 | |
| US61/875,220 | 2013-09-09 | ||
| PCT/US2014/054489 WO2015035278A1 (en) | 2013-09-09 | 2014-09-08 | RORγ MODULATORS |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016532715A JP2016532715A (ja) | 2016-10-20 |
| JP2016532715A5 JP2016532715A5 (OSRAM) | 2017-10-19 |
| JP6407285B2 true JP6407285B2 (ja) | 2018-10-17 |
Family
ID=51541401
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016540455A Expired - Fee Related JP6407285B2 (ja) | 2013-09-09 | 2014-09-08 | RORγ調節因子 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US9663469B2 (OSRAM) |
| EP (1) | EP3044219A1 (OSRAM) |
| JP (1) | JP6407285B2 (OSRAM) |
| CN (1) | CN105705501B (OSRAM) |
| WO (1) | WO2015035278A1 (OSRAM) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015035278A1 (en) | 2013-09-09 | 2015-03-12 | Bristol-Myers Squibb Company | RORγ MODULATORS |
| EP3046906B1 (en) | 2013-09-20 | 2017-08-16 | Bristol-Myers Squibb Company | Ror gamma modulators |
| CN106061947B (zh) | 2014-01-06 | 2019-12-03 | 百时美施贵宝公司 | 环己基砜RORγ调节剂 |
| EP3092221B1 (en) | 2014-01-06 | 2018-10-17 | Bristol-Myers Squibb Company | Heterocyclic sulfones as ror-gamma modulators |
| CN106132931B (zh) | 2014-01-06 | 2019-08-02 | 百时美施贵宝公司 | 碳环砜RORγ调节剂 |
| US9845319B2 (en) | 2014-10-30 | 2017-12-19 | Janssen Pharmaceutiuca NV | Amide substituted thiazoles as modulators of RORyt |
| CN107108598B (zh) | 2014-10-30 | 2020-11-17 | 詹森药业有限公司 | 作为Rorγt调节剂的噻唑 |
| JOP20200117A1 (ar) | 2014-10-30 | 2017-06-16 | Janssen Pharmaceutica Nv | كحولات ثلاثي فلوروميثيل كمُعدلات للمستقبل النووي جاما تي المرتبط بحمض الريتيونَويك ROR?t |
| UY36673A (es) | 2015-05-07 | 2016-11-30 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | Sulfonas tricíclicas como moduladores de ror y composiciones farmacéuticas que las contienen |
| AU2016276947A1 (en) * | 2015-06-11 | 2017-12-14 | Lycera Corporation | Aryl dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORy and the treatment of disease |
| CN104892546B (zh) * | 2015-07-01 | 2017-03-01 | 中国科学院南海海洋研究所 | 一类(2h)1,4‑苯并噻嗪类化合物及其制备方法和应用 |
| EP3330256B1 (en) * | 2015-07-07 | 2021-06-16 | Shionogi & Co., Ltd. | HETEROCYCLIC DERIVATIVE HAVING TrkA-INHIBITING ACTIVITY |
| TW201803869A (zh) | 2016-04-27 | 2018-02-01 | 健生藥品公司 | 作為RORγT調節劑之6-胺基吡啶-3-基噻唑 |
| HUE071358T2 (hu) | 2016-05-20 | 2025-08-28 | Xenon Pharmaceuticals Inc | Benzolszulfonamid vegyületek és terápiás szerként való alkalmazásuk |
| WO2017213210A1 (ja) * | 2016-06-10 | 2017-12-14 | 武田薬品工業株式会社 | 複素環化合物 |
| JP7022751B2 (ja) | 2016-12-09 | 2022-02-18 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | ベンゼンスルホンアミド化合物および治療剤としてのそれらの使用 |
| US10822318B2 (en) * | 2017-05-24 | 2020-11-03 | Regents Of The University Of Minnesota | Lactone-based probes and methods of use thereof |
| JP2020142989A (ja) * | 2017-06-21 | 2020-09-10 | Meiji Seikaファルマ株式会社 | イミダゾール誘導体及びそれを含有する医薬 |
| CN112118841A (zh) * | 2018-03-12 | 2020-12-22 | 爱思凯利尔生物科学私人有限责任公司 | 螺环ROR-γ调节剂 |
| EP3765009A4 (en) | 2018-03-12 | 2021-11-10 | Escalier Biosciences, BV | BICYCLIC ROR-GAMMA MODULATORS |
| SG11202011862PA (en) | 2018-06-13 | 2020-12-30 | Xenon Pharmaceuticals Inc | Benzenesulfonamide compounds and their use as therapeutic agents |
| EP3790865A1 (en) | 2018-06-18 | 2021-03-17 | Janssen Pharmaceutica NV | Phenyl substituted pyrazoles as modulators of roryt |
| ES2928246T3 (es) | 2018-06-18 | 2022-11-16 | Janssen Pharmaceutica Nv | 6-aminopiridin-3-il pirazoles como moduladores de RORyt |
| JP2021527660A (ja) | 2018-06-18 | 2021-10-14 | ヤンセン ファーマシューティカ エヌ.ベー. | RORγtのモジュレータとしてのフェニル及びピリジニル置換イミダゾール |
| ES2925473T3 (es) | 2018-06-18 | 2022-10-18 | Janssen Pharmaceutica Nv | Pirazoles de piridinilo como moduladores de RORyt |
| CN112119065B (zh) * | 2018-07-13 | 2024-01-23 | 四川科伦博泰生物医药股份有限公司 | 苯并二氮杂环类化合物、其制备方法及用途 |
| CN112638898B (zh) | 2018-08-31 | 2024-04-09 | 泽农医药公司 | 杂芳基取代的磺酰胺化合物及其作为钠通道抑制剂的用途 |
| MX2021001380A (es) | 2018-08-31 | 2021-05-27 | Xenon Pharmaceuticals Inc | Compuestos de sulfonamida sustituidos con heteroarilo y su uso como agentes terapeuticos. |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20012060A1 (it) * | 2001-10-05 | 2003-04-05 | Recordati Chem Pharm | Nuovi eterocilcli n-acilati |
| US7741317B2 (en) * | 2005-10-21 | 2010-06-22 | Bristol-Myers Squibb Company | LXR modulators |
| EP2368886A1 (en) * | 2010-03-01 | 2011-09-28 | Phenex Pharmaceuticals AG | Novel compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (ROR gamma, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune desease |
| CA2816753A1 (en) * | 2010-11-08 | 2012-05-18 | Lycera Corporation | N- sulfonylated tetrahydroquinolines and related bicyclic compounds inhibition of rory activity and the treatment of diseases |
| WO2013064231A1 (en) * | 2011-10-31 | 2013-05-10 | Phenex Pharmaceuticals Ag | SEVEN-MEMBERED SULFONAMIDES AS MODULATORS OF RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORγ, NR1F3) |
| PE20150778A1 (es) | 2012-10-16 | 2015-05-23 | Janssen Pharmaceutica Nv | Moduladores de quinolinilo unidos a metileno de ror-gamma-t |
| US10035790B2 (en) | 2012-10-19 | 2018-07-31 | Exelixis, Inc. | RORγ modulators |
| WO2015035278A1 (en) | 2013-09-09 | 2015-03-12 | Bristol-Myers Squibb Company | RORγ MODULATORS |
| EP3046906B1 (en) | 2013-09-20 | 2017-08-16 | Bristol-Myers Squibb Company | Ror gamma modulators |
| ES2669208T3 (es) | 2014-01-06 | 2018-05-24 | Bristol-Myers Squibb Company | Derivados de pirrolidinilsulfona y su uso como moduladores de ROR gamma |
| EP3092221B1 (en) | 2014-01-06 | 2018-10-17 | Bristol-Myers Squibb Company | Heterocyclic sulfones as ror-gamma modulators |
| CN106061947B (zh) | 2014-01-06 | 2019-12-03 | 百时美施贵宝公司 | 环己基砜RORγ调节剂 |
| CN106132931B (zh) | 2014-01-06 | 2019-08-02 | 百时美施贵宝公司 | 碳环砜RORγ调节剂 |
-
2014
- 2014-09-08 WO PCT/US2014/054489 patent/WO2015035278A1/en not_active Ceased
- 2014-09-08 JP JP2016540455A patent/JP6407285B2/ja not_active Expired - Fee Related
- 2014-09-08 EP EP14766373.6A patent/EP3044219A1/en not_active Withdrawn
- 2014-09-08 US US14/917,420 patent/US9663469B2/en active Active
- 2014-09-08 CN CN201480061168.1A patent/CN105705501B/zh not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN105705501A (zh) | 2016-06-22 |
| US9663469B2 (en) | 2017-05-30 |
| EP3044219A1 (en) | 2016-07-20 |
| CN105705501B (zh) | 2019-04-19 |
| WO2015035278A1 (en) | 2015-03-12 |
| US20160318870A1 (en) | 2016-11-03 |
| JP2016532715A (ja) | 2016-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6407285B2 (ja) | RORγ調節因子 | |
| US10544133B2 (en) | Heteroaryl substituted pyridyl compounds useful as kinase modulators | |
| EP3046906B1 (en) | Ror gamma modulators | |
| JP6530764B2 (ja) | RORγ調節因子としてのピロリジニルスルホン誘導体およびその使用 | |
| US9732087B2 (en) | Diamino-pyridine, pyrimidine, and pyridazine modulators of the histamine H4 receptor | |
| US20180230157A1 (en) | PYRROLO[1,2-b]PYRIDAZINE DERIVATIVES | |
| TW201718570A (zh) | B型肝炎核心蛋白質調節劑 | |
| JP2017509689A (ja) | シクロヘキシルスルホンRORγ調節因子 | |
| US11332459B2 (en) | Benzimidazole derivatives and their uses | |
| JP2023509495A (ja) | RORγt阻害剤、その製造方法及び使用 | |
| US10934286B2 (en) | Heterocyclic sulfones as ROR gamma modulators | |
| EP4263548B1 (en) | Dihydrofuropyridine derivatives as rho- kinase inhibitors | |
| CN113072538A (zh) | RORγt抑制剂及其在药物中的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170907 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170907 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20180517 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180522 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180718 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180821 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180918 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6407285 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |